136 related articles for article (PubMed ID: 16182279)
1. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats.
Byrnes-Blake KA; Laurenzana EM; Landes RD; Gentry WB; Owens SM
Eur J Pharmacol; 2005 Oct; 521(1-3):86-94. PubMed ID: 16182279
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
3. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat.
McMillan DE; Hardwick WC; Li M; Gunnell MG; Carroll FI; Abraham P; Owens SM
J Pharmacol Exp Ther; 2004 Jun; 309(3):1248-55. PubMed ID: 14993256
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.
Byrnes-Blake KA; Laurenzana EM; Carroll FI; Abraham P; Gentry WB; Landes RD; Owens SM
Eur J Pharmacol; 2003 Feb; 461(2-3):119-28. PubMed ID: 12586207
[TBL] [Abstract][Full Text] [Related]
5. Drug interaction between methamphetamine and antihistamines: behavioral changes and tissue concentrations of methamphetamine in rats.
Okuda T; Ito Y; Nakagawa N; Hishinuma T; Tsukamoto H; Iwabuchi K; Watanabe T; Kitaichi K; Goto J; Yanai K
Eur J Pharmacol; 2004 Nov; 505(1-3):135-44. PubMed ID: 15556146
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.
Hardin JS; Wessinger WD; Proksch JW; Owens SM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1113-22. PubMed ID: 9618414
[TBL] [Abstract][Full Text] [Related]
7. Development of murine monoclonal antibodies to methamphetamine and methamphetamine analogues.
Danger Y; Gadjou C; Devys A; Galons H; Blanchard D; Folléa G
J Immunol Methods; 2006 Feb; 309(1-2):1-10. PubMed ID: 16412457
[TBL] [Abstract][Full Text] [Related]
8. Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies.
Nguyen EC; McCracken KA; Liu Y; Pouw B; Matsumoto RR
Neuropharmacology; 2005 Oct; 49(5):638-45. PubMed ID: 15939443
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats.
Pentel PR; Dufek MB; Roiko SA; Lesage MG; Keyler DE
J Pharmacol Exp Ther; 2006 May; 317(2):660-6. PubMed ID: 16407464
[TBL] [Abstract][Full Text] [Related]
11. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted.
Pitas G; Laurenzana EM; Williams DK; Owens SM; Gentry WB
Drug Metab Dispos; 2006 Jun; 34(6):906-12. PubMed ID: 16507651
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine.
Zhang L; Kitaichi K; Fujimoto Y; Nakayama H; Shimizu E; Iyo M; Hashimoto K
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1381-93. PubMed ID: 16839653
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody.
McMillan DE; Hardwick WC; Li M; Owens SM
Behav Pharmacol; 2002 Sep; 13(5-6):465-73. PubMed ID: 12394422
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships.
Keyler DE; Roiko SA; Benlhabib E; LeSage MG; St Peter JV; Stewart S; Fuller S; Le CT; Pentel PR
Drug Metab Dispos; 2005 Jul; 33(7):1056-61. PubMed ID: 15843487
[TBL] [Abstract][Full Text] [Related]
15. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.
Peterson EC; Laurenzana EM; Atchley WT; Hendrickson HP; Owens SM
J Pharmacol Exp Ther; 2008 Apr; 325(1):124-33. PubMed ID: 18192498
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for the treatment of drug abuse.
Kosten T; Owens SM
Pharmacol Ther; 2005 Oct; 108(1):76-85. PubMed ID: 16023218
[TBL] [Abstract][Full Text] [Related]
17. Blockade of M1 muscarinic acetylcholine receptors modulates the methamphetamine-induced psychomotor stimulant effect.
Lee KW; Tian YH; You IJ; Kwon SH; Ha RR; Lee SY; Kim HC; Jang CG
Neuroscience; 2008 Jun; 153(4):1235-44. PubMed ID: 18455881
[TBL] [Abstract][Full Text] [Related]
18. A sensitizing regimen of methamphetamine causes impairments in a novelty preference task of object recognition.
Belcher AM; O'Dell SJ; Marshall JF
Behav Brain Res; 2006 Jun; 170(1):167-72. PubMed ID: 16600393
[TBL] [Abstract][Full Text] [Related]
19. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
[TBL] [Abstract][Full Text] [Related]
20. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice.
Ago Y; Nakamura S; Uda M; Kajii Y; Abe M; Baba A; Matsuda T
Neuropharmacology; 2006 Sep; 51(4):914-22. PubMed ID: 16863654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
